GMO Equity Dislocation Fund (Offshore), L.P.

With eight named GPs and no prior EDGAR filings on record, GMO is either a newly formed partnership or a carve-out from a larger institution that did not previously raise under this legal entity; the GP count and offshore domicile suggest this manager is operationalizing a specialized team around dislocation-focused strategies without prior fund infrastructure.

A May 2026 filing for an equity dislocation fund arrives in a period of elevated volatility and valuation dispersion post-correction, when liquid markets create mispricing opportunities that hedge funds can arbitrage — the timing reflects tactical positioning into an environment where the fund's stated thesis has renewed relevance.

Verify whether any of the eight named GPs hold key-person provisions tied to fund deployments, and confirm whether this amendment signals a target increase, LP substitution, or extension of a previously filed initial offering — the amendment status suggests material changes mid-raise that require tracing back to the original filing.